the effect of synbiotic supplementation on poly cystic ovarian syndrome

The effect of synbiotic on insulin resistance, gut microbiota, sex hormones and morphology of ovaries’ cysts in women with poly cystic ovarian syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017050233767N1

Enrollment

Registered

2017-09-22

Start date

2017-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

poly cystic ovarian syndrome. ovarian dysfunction

Interventions

Intervention 1: intervention group: 1 capsule ( 500 mg of synbiotic supplementation)/ daily/ 2 months. Intervention 2: control group: 1 placebo supplementation/ daily/ 2 months.

Treatment - Drugs

intervention group: 1 capsule ( 500 mg of synbiotic supplementation)/ daily/ 2 months

control group: 1 placebo supplementation/ daily/ 2 months

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: The willingness to collaborate in the plan, being between the ages of 18 and 45, has at least two criteria of Rotterdam's three criteria for detecting the syndrome and having a BMI of between 25 and 35 kg / m². exclusion criteria: Unwillingness to continue to participate in the study, inadequate supplementation (less than 80% of supplements), and the achievement of any non-inclusion criteria including pregnancy, lactation, menopause, drug use during the past three months include contraceptives, glucocorticoid, Lipid-lowering drugs, Weight loss drugs, Ovulation induction drugs, Estrogenic or anti-androgenic drugs, Underlying illnesses, Infectious diseases, Inflammatory disease, Adrenal gland abnormal, Cushing's syndrome, Adrenal gland tumor, Low Hyperthyroidism, Prolactinemia, Acromegaly, Diabetes and Cancer, Hormone Therapy over 3 months Past and use of probiotic, prebiotic and synbiotic supplements over the past 3 months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sex hormones. Timepoint: at first/ end of study. Method of measurement: elisa.	—

Secondary

Measure	Time frame
Serum insulin. Timepoint: at first/ end of study. Method of measurement: elisa.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Aghayan

Health school, Qazvin university of medical sciences

maryam.aghayan9@gmail.com+98 28333360013750

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026